Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Cefepime/taniborbactam - VenatoRx Pharmaceuticals

Next Previous
X
Search
Drug Profile

Cefepime/taniborbactam - VenatoRx Pharmaceuticals

Alternative Names: Cefepime/VNRX-5133; VNRX-5133/VNRX-5022; VNRX5133/Cefepime

Latest Information Update: 29 Aug 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator VenatoRx Pharmaceuticals
  • Developer Global Antibiotic Research and Development Partnership; VenatoRx Pharmaceuticals
  • Class Anti-inflammatories; Antibacterials; Beta-lactams; Cephalosporins; Small molecules
  • Mechanism of Action Beta lactamase inhibitors; Cell wall inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preregistration Pyelonephritis; Urinary tract infections
  • Preclinical Nosocomial pneumonia

Most Recent Events

  • 28 Aug 2024 Everest Medicines announces intention to submit NDA to NMPA for Urinary tract infections (Complicated) in mainland China, in 2025
  • 30 May 2024 Preclinical trials in Nosocomial pneumonia in USA (IV), before May 2024 (VenatoRx Pharmaceuticals website, May 2024)
  • 30 May 2024 The EMA approves Paediatric Investigation Plan for cefepime/taniborbactam, before May 2024 (VenatoRx Pharmaceuticals website, May 2024)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top